{"filing":{"accession_number":"0001477932-26-004001","cik":"0001464165","ticker":"BETRF","company_name":"BetterLife Pharma Inc.","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"betrf_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1464165/000147793226004001/betrf_6k.htm"},"events":[{"id":13831,"run_id":12286,"accession_number":"0001477932-26-004001","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The exhibit discloses multiple equity issuances and dilutive transactions: a CAD $2M convertible debenture financing (convertible at $0.06/unit with warrants), a private placement of 7.1M units at $0.07/unit, stock option grants totaling 6.75M shares, and warrant extensions. The convertible debenture and private placement are the primary material events, representing significant capital raises through dilutive securities. While the exhibit also covers warrant extensions and executive appointments, the dominant disclosure is the equity financing activity.","company_name":"BetterLife Pharma Inc.","ticker":"BETRF","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":11092,"accession_number":"0001477932-26-004001","item_number":"EX-99.1","item_title":"betrf_ex991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The exhibit discloses multiple equity issuances and dilutive transactions: a CAD $2M convertible debenture financing (convertible at $0.06/unit with warrants), a private placement of 7.1M units at $0.07/unit, stock option grants totaling 6.75M shares, and warrant extensions. The convertible debenture and private placement are the primary material events, representing significant capital raises through dilutive securities. While the exhibit also covers warrant extensions and executive appointments, the dominant disclosure is the equity financing activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T18:27:39.275772+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11092,"accession_number":"0001477932-26-004001","item_number":"EX-99.1","item_title":"betrf_ex991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The exhibit discloses multiple equity issuances and dilutive transactions: a CAD $2M convertible debenture financing (convertible at $0.06/unit with warrants), a private placement of 7.1M units at $0.07/unit, stock option grants totaling 6.75M shares, and warrant extensions. The convertible debenture and private placement are the primary material events, representing significant capital raises through dilutive securities. While the exhibit also covers warrant extensions and executive appointments, the dominant disclosure is the equity financing activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T18:27:39.275772+00:00","company_name":"BetterLife Pharma Inc.","ticker":"BETRF","filing_date":"2026-06-25"}]}